Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its conversion and listing process, indicating that the filing has been completed [1] Group 1: Filing and Listing Process - The company received the filing notice on February 5, 2026, confirming the completion of the CSRC filing for conversion and listing [1] - If the company does not complete the share conversion within 12 months from the issuance of the filing notice, it must update the CSRC with new filing materials if it wishes to continue the process [1] - Details of the implementation plan for the conversion and listing have not yet been finalized as of the announcement date [1] Group 2: Compliance and Future Announcements - The company will make further announcements regarding the progress of the conversion and listing in accordance with listing rules and applicable laws and regulations [1]
泰德医药(03880)：中国证监会就公司H股全流通申请发出备案通知书